Dr Brandon Shank: Pharmacist Education on Biosimilars

Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the importance of pharmacist education on biosimilar treatments.
August 17, 2017


Transcript (Slightly Edited):

Education is paramount with the implementation of biosimilars for pharmacists. Currently, there is an education gap because the FDA is finalizing the naming documents and how these drugs will be approved and make it to market. As more drugs become available, this gap will close, and pharmacists will become more used to seeing these in practice and utilizing these agents. They will become more familiar with the packaging differences, the naming, and the indications of use. So, they will be able to dispense these products with confidence.

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.